题目：Synthesis of Biologically Active Natural Products and Rare Heterocycles

报告人：Professor A. Ganesan， School of Pharmacy，University of East Anglia

报告时间：2017年3月30日（周四）上午10:30

地点：化学馆120

Ganesan obtained a BSc (Hons) in Chemistry at the National University of Singapore (1986). He completed his PhD in synthetic methodology and total synthesis under the supervision of Clayton Heathcock at the Department of Chemistry, University of California-Berkeley (1992), followed by a postdoctoral stint with Gregory Verdine at the Department of Chemistry at Harvard University. In 1993, he joined the Institute of Molecular and Cell Biology in Singapore as a Senior Research Chemist at the Centre for Natural Product Research and in 1996 became Principal Investigator of the Institute’s Medicinal and Combinatorial Chemistry group. In 1999 he joined the University of Southampton as a Reader in the Combinatorial Chemistry Centre for Excellence. In 2011 he became the Chair of Chemical Biology at UEA’s School of Pharmacy. He is Director of Postgraduate Research and Head of the Medicinal Chemistry section within the School.

Ganesan is co-founder of the biotech company Karus Therapeutics and Chair of the EU COST Action TD0905, 'Epigenetics: From Bench to Bedside'. He is Treasurer of the Royal Society of Chemistry's High Throughput Chemistry and New Technologies subject group and sits on the IUPAC Subcommittee for Medicinal Chemistry and Drug Development.

Ganesan's research centres around chemical biology, medicinal chemistry and organic synthesis with an emphasis on biologically active natural products and epigenetics. Projects are usually interdisciplinary and involve collaborations with other research groups worldwide. Currently, there are active collaborations with Lucia Altucci, University of Naples, Italy; Flavio Emery, University of Sao Paulo-Ribeirao Preto, Brazil; Claudio Lopes, Federal University of Rio de Janeiro, Brazil; Marc Stadler, Helmholtz Centre for Infection Research, Germany and Shijun Wen, Sun Yat-sen University, China. Ganesan is part of the EU funded consortium AParaDDisE, Anti-Parasitic Drug Discovery in Epigenetics together with researchers from Australia, Brazil, France, Germany, Italy and Sweden.